Dominari (NASDAQ:DOMH) Releases Quarterly Earnings Results, Misses Estimates By $9.26 EPS

Dominari (NASDAQ:DOMH) released its quarterly earnings results on Tuesday. The company reported ($9.43) EPS for the quarter, missing the consensus estimate of ($0.17) by ($9.26), FiscalAI reports. Dominari had a negative return on equity of 50.80% and a net margin of 110.86%.

Dominari Stock Down 1.0%

Shares of DOMH stock opened at $2.85 on Tuesday. The firm has a 50 day moving average of $3.41 and a two-hundred day moving average of $4.58. The stock has a market capitalization of $46.23 million, a PE ratio of 0.51 and a beta of 0.83. Dominari has a 52 week low of $2.75 and a 52 week high of $8.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Trading of Dominari

Several hedge funds have recently modified their holdings of DOMH. Creek Drive Management Group LLC acquired a new position in Dominari during the 4th quarter worth $1,861,000. Two Sigma Investments LP purchased a new position in shares of Dominari in the 3rd quarter valued at about $771,000. Renaissance Technologies LLC purchased a new position in shares of Dominari in the 4th quarter valued at about $412,000. Connective Capital Management LLC grew its position in shares of Dominari by 26.2% during the third quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock worth $2,377,000 after buying an additional 69,545 shares in the last quarter. Finally, Susquehanna Advisors Group Inc. acquired a new position in shares of Dominari during the fourth quarter worth about $182,000. 42.48% of the stock is currently owned by institutional investors and hedge funds.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.